Litcius/Paper detail

NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer

Junping Li, Hong Hu, Hui Lian, Shuo Yang, Manting Liu, Jinping He, Bihui Cao, Dongni Chen, Yuling Hu, Cheng Zhi, Yan Shen, Xiaodie Ye, Bingjia He, Ming Zhao, Weijun Fan, Linfeng Xu, Rom S. Leidner, Qingde Wu, Lili Yang, Zhenfeng Zhang

2024International Journal of Biological Sciences30 citationsDOIOpen Access PDF

Abstract

: These results indicate that CLDN6-CAR NK cells possess strong antitumor activity and represent a promising immunotherapeutic modality for ovarian cancer.

Topics & Concepts

Chimeric antigen receptorCytotoxic T cellCancer researchOvarian cancerNKG2DBiologyAntigenWestern blotImmunotherapyMolecular biologyCancerIn vitroImmunologyImmune systemGeneGeneticsBiochemistryImmune Cell Function and InteractionCAR-T cell therapy researchReproductive System and Pregnancy
NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer | Litcius